ROCKVILLE, Md., April 28, 2021 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX) today announced that it will host a conference call
on Wednesday, May 5, 2021, at
4:30 p.m. ET to discuss its financial
results for the quarter ended March 31,
2021, and recent operational highlights.
To access the live call by phone, dial (855) 422-8964 (domestic)
or (210) 229-8819 (international) and enter the
passcode 7044809. To access a live or recorded webcast of the
call, please visit the Investors section of the REGENXBIO website
at www.regenxbio.com. The recorded webcast will be available for
approximately 30 days following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV® Technology Platform, a
proprietary adeno-associated virus (AAV) gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its
third-party NAV Technology Platform Licensees are applying the NAV
Technology Platform in the development of a broad pipeline of
candidates in multiple therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-may-5-to-discuss-first-quarter-2021-financial-results-and-recent-operational-highlights-301279354.html
SOURCE REGENXBIO Inc.